Form 4: Lyra Therapeutics Director Michael Altman Acquires 30,000 Stock Options

Director Michael Seth Altman acquired 30,000 stock options in Lyra Therapeutics, Inc. on June 13, 2024.

Summary

• Michael Seth Altman, a director of Lyra Therapeutics, Inc., reported a transaction involving derivative securities.
• On June 13, 2024, Altman acquired 30,000 stock options with an exercise price of $0.31.
• These options vest on the earlier of June 13, 2025, or the day before the next annual meeting of stockholders after the grant date, contingent on continued service as a non-employee director.
• Following the transaction, Altman directly owns 30,000 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of stock option grants to a director. It doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders, allowing investors to assess their confidence in the company's prospects.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding director compensation and alignment of interests.

Key Dates

Keywords

Lyra Therapeutics, Stock Options, Form 4, Director, Altman, Beneficial Ownership, Securities